14464-15-4

Basic information

• Product Name: methyl 2-{[(benzyloxy)carbonyl]amino}-3-hydroxypropanoate
• Synonyms: methyl 2-{[(benzyloxy)carbonyl]amino}-3-hydroxypropanoate;N-Cbz-DL-serine Methyl Ester;Cbz-DL-Ser-OMe;Z-DL-Ser-ome
• CAS NO: 14464-15-4
• Molecular Formula: C₁₂H₁₅NO₅
• Molecular Weight: 253
• Mol File: 14464-15-4.mol
• Article Data: 15

Chemical Properties

• Melting Point: 42 °C
• Boiling Point: 442.6ºC at 760 mmHg
• Flash Point: 221.5ºC
• Appearance: /
• Density: 1.254g/cm3
• Vapor Pressure: 1.3E-08mmHg at 25°C
• Refractive Index: 1.536
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 10.49±0.46(Predicted)
• CAS DataBase Reference: methyl 2-{[(benzyloxy)carbonyl]amino}-3-hydroxypropanoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 2-{[(benzyloxy)carbonyl]amino}-3-hydroxypropanoate(14464-15-4)
• EPA Substance Registry System: methyl 2-{[(benzyloxy)carbonyl]amino}-3-hydroxypropanoate(14464-15-4)

Safety Data

• Hazardous Substances Data: 14464-15-4(Hazardous Substances Data)

Usage

Description

Methyl 2-[(benzyloxy)carbonyl]amino-3-hydroxypropanoate is a chemical compound that features a methyl ester group, a hydroxypropanoate backbone, and a benzyloxycarbonyl-protected amino group. This structure makes it a versatile building block in organic synthesis and a potential candidate for various applications in the pharmaceutical and chemical industries.

Uses

Used in Pharmaceutical Industry:
Methyl 2-[(benzyloxy)carbonyl]amino-3-hydroxypropanoate is used as an intermediate for the synthesis of biologically active molecules. Its unique structure allows for the development of novel drugs with potential applications in various therapeutic areas.
Used in Chemical Synthesis:
In the chemical synthesis industry, methyl 2-[(benzyloxy)carbonyl]amino-3-hydroxypropanoate is used as a key building block for the creation of complex organic molecules. Its functional groups can be further modified to produce a wide range of compounds with specific properties and applications.
Used in Research and Development:
Methyl 2-[(benzyloxy)carbonyl]amino-3-hydroxypropanoate is also utilized in research and development settings, where it can be employed to study the properties and reactivity of similar compounds. This can lead to the discovery of new synthetic routes and the development of innovative applications in various fields.

Synthesis Reference(s)

Journal of the American Chemical Society, 75, p. 3469, 1953 DOI: 10.1021/ja01110a049

InChI:InChI=1/C12H15NO5/c1-17-11(15)10(7-14)13-12(16)18-8-9-5-3-2-4-6-9/h2-6,10,14H,7-8H2,1H3,(H,13,16)

Upstream product

• 5619-04-5 methyl 2-amino-3-hydroxypropanoate hydrochloride 
• 75-77-4 chloro-trimethyl-silane 
• 2768-56-1 Z-DL-serine 
• 2104-89-4 Ser-OMe 
• 501-53-1 benzyl chloroformate 
• 6081-61-4 N-(benzyloxycarbonyl)-D-serine 
• 957208-94-5 2-benzyloxycarbonylamino-3-(tert-butyl-dimethyl-silanyloxy)-propionic acid methyl ester 
• 124-41-4 sodium methylate 
• 98632-91-8 N-(benzyloxycarbonyl)-D-serine-β-lactone 
• 186581-53-3 diazomethane 
• 67-56-1 methanol 

Downstream Products

• 85472-28-2 N^α-Benzyloxycarbonyl-serin-amid 
• 155526-66-2 (R)-methyl 2-(benzyloxycarbonylamino)-3-t-butoxypropanoate 
• 94031-74-0 O-(hydroxy-phenoxy-phosphoryl)-serine methyl ester 
• 957208-94-5 2-benzyloxycarbonylamino-3-(tert-butyl-dimethyl-silanyloxy)-propionic acid methyl ester 
• 21142-81-4 methyl N-[(benzyloxy)carbonyl]-O-tosyl-L-serinate 
• 1309370-66-8 C₁₇H₂₇NO₄Si 
• 1312306-44-7 (R,S)-2-(N-benzyloxycarbonylamino)-3-(N'-methylamino)propionic acid methyl ester 
• 1312306-45-8 (R,S)-N-methyl 2-(N'-benzyloxycarbonylamino)-3-(N-methylamino)propionamide 
• 1312306-39-0 (R,S)-2-(N-benzyloxycarbonylamino)-3-(N',N'-dimethylamino)propionic acid methyl ester 
• 208259-59-0 (R,S)-2-(N-benzyloxycarbonylamino)-3-morpholinopropionic acid methyl ester 
• 1312306-40-3 (R,S)-N-benzyl 2-(N'-benzyloxycarbonylamino)-3-(N,N-dimethylamino)propionamide 
• 1312306-42-5 (R,S)-N-benzyl 2-(N'-benzyloxycarbonylamino)-3-morpholinopropionamide 
• 170701-87-8 L-1-Benzyloxycarbonylaziridine-2-carboxylic acid methyl ester 
• 838-85-7 diphenyl hydrogen phosphate 

Relevant articles and documents

Method for synthesizing benserazide hydrochloride by utilizing fixed bed hydrogenation equipment

The invention discloses a method for synthesizing benserazide hydrochloride by using fixed bed hydrogenation equipment, which is characterized in that a compound 1 reacts with an amino protective agent to carry out an amino protection reaction, so that the subsequent purification is easy, and the dosage of hydrazine hydrate in the synthesis method is small; according to the method, fixed bed hydrogenation equipment is used for synthesis, a fixed bed reactor is filled with a solid catalyst or a solid to realize a heterogeneous reaction process, the catalyst in the fixed bed reactor is relatively fixed, a reaction liquid flows through a bed layer, and the reaction liquid flows through the bed layer by adjusting the flow rate and the reaction pressure; qualified products can be obtained after reaction liquid flows out of the fixed bed, continuous production can be achieved, product deterioration caused by long-time contact of the products and the catalyst can be avoided, the same amount of products can be produced due to continuous production, the reactor size can be very small, the safety problem caused by high-pressure reaction is greatly reduced, the amount of the catalyst used in the reaction is less, and the production cost is reduced.

An innovative strategy for the synthesis of a new series of potent aminopeptidase (APN or CD13) inhibitors derived from the oxepin-4-one family

Derivatives from the aminobenzosuberone family have been recently synthesized and recognized as highly selective inhibitors of aminopeptidase N (APN)/CD13 (EC 3.4.11.2), an important target for cell migration processes involved in particular in tumor inva

NOVEL INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP)

A compound having the structure set forth in Formula (I): wherein the variables Y, R1, R2, R3, R4 and R5 are as defined herein. Compounds described herein are inhibitors of poly(ADP-ribose)polymerase activity. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of such compounds and pharmaceutical compositions to treat diseases, disorders and conditions that are ameliorated by the inhibition of PARP activity